Abstract
Bladder pain syndrome (BPS) should be regarded as a true pain syndrome (a collection of symptoms and signs which, together, characterize a particular condition or disease) rather than an end-organ disease. The term “interstitial cystitis” (IC) has been a misleading name for a condition in which true bladder inflammation is seen only in a small subset of patients with chronic bladder pain. Furthermore, the lack of consensus as to what constitutes IC has hindered progress in the understanding of what is now called BPS. By definition, BPS/IC it consists of “the complaint of suprapubic pain related to bladder filling accompanied by other symptoms, such as increased daytime and nighttime frequency, in the absence of proven urinary infection or other obvious pathology” [1, 2]. The precise etiology and pathogenesis of BPS/IC is unknown, but the overwhelming majority of patients with BPS/IC are female (F:M = 10:1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bade JJ, Laseur M, Nieuwenburg A, van der Weele LT, Mensink HJ (1997) A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis. Br J Urol 79(2):168–171
Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pfluger H (2005) Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 47(3):393–397; discussion 397
Fall M, Oberpenning F, Peeker R (2008) Treatment of bladder pain syndrome/interstitial cystitis 2008; can we make evidence-based decisions? Eur Urol 54(1):65–75
Fritjofsson A, Fall M, Juhlin R, Persson BE, Ruutu M (1987) Treatment of ulcer and nonulcer interstitial cystitis with sodium pentosanpolysulfate: a multicenter trial. J Urol 138(3):508–512
Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E (2008) Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J Urol 179(3):1031–1034
http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/CPP.pdf
Irwin P (2008) Recent developments in BPS/IC. Urol News 12(10):6–11
Irwin P, Galloway NTM (1993) Impaired bladder perfusion in interstitial cystitis: a study using laser doppler flowmetry. J Urol 149(4):890–892
Irwin P, Samsudin A (2005) Reinvestigation of patients with a diagnosis of interstitial cystitis: common things are sometimes common. J Urol 174(2):584–587
Kanai A, de Groat W, Chai T, Hultgren S, Fowler C, Fry C (2006) Symposium on urothelial dysfunction: pathophysiology and novel therapies. J Urol 175(5):1624–1629
Karsenty G, AlTaweel W, Hajebrahimi S, Corcos J (2006) Efficacy of interstitial cystitis treatments: a review. EAU-EBU Update Series 4:47–61
Morales A, Emerson L, Nickel JC, Lundie M (1996) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156(1):45–48
Nordling J, Jorgensen S, Kallestrup E (2001) Cystistat for the treatment of interstitial cystitis: a 3-year followup study. Urology 57(6 Suppl 1):123
Perez-Marrero R, Emerson LE, Feltis JT (1988) A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol 140(1):36–39
Pontari MA, Hanno PM, Ruggieri MR (1999) Comparison of bladder blood flow in patients with and without interstitial cystitis. J Urol 162(2):330–334
Ramsay AK, Small DR, Conn IG (2007) Intravesical botulinum toxin type A in chronic interstitial cystitis: results of a pilot study. Surgeon 5(6):331–333
Rössberger J, Fall M, Peeker R (2005) Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: discomfort, side-effects and treatment outcome. Scand J Urol Nephrol 39(1):73–77
Sairanen J, Hotakainen K, Tammela TL, Stenman UH, Ruutu M (2008) Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium. Urology 71(4):630–633
GR Sant (ed) (1996) Interstitial cystitis – the neurovascular perspective in interstitial cystitis. Raven Press, New York
Sant GR, LaRock DR (1994) Standard intravesical therapies for interstitial cystitis. Urol Clin North Am 21(1):73–83
Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC, Hardy C, Landis JR, Mayer R, Madigan R, Messing EM, Peters K, Theoharides TC, Warren J, Wein AJ, Steers W, Kusek JW, Nyberg LM (2003) Interstitial cystitis clinical trials group. a pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 170(3):810–815
Sorensen RB (2003) Chondroitin sulphate in the treatment of interstitial cystitis and chronic inflammatory disease of the urinary bladder. Eur Urol 2:16–18
Steinhoff G (2003) The efficacy of chondroitin sulfate in treating interstitial cystitis. Eur Urol 2:14–16
van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, Mortensen S, van Ophoven A, Osborne JL, Peeker R, Richter B, Riedl C, Sairanen J, Tinzl M, Wyndaele JJ (2008) Diagnostic criteria, classification and nomenclature for painful bladder syndrome/interstitial cystitis. Eur Urol 53(1):60–67
van Ophoven A, Heinecke A, Hertle L (2005) Safety and efficacy of concurrent application of oral pentosan polysulfate and subcutaneous low-dose heparin for patients with interstitial cystitis. Urology 66(4):707–711
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag London
About this chapter
Cite this chapter
Irwin, P. (2010). Bladder Pain Syndrome/Interstitial Cystitis. In: Shergill, I., Arya, M., Grange, P., Mundy, A. (eds) Medical Therapy in Urology. Springer, London. https://doi.org/10.1007/978-1-84882-704-2_9
Download citation
DOI: https://doi.org/10.1007/978-1-84882-704-2_9
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84882-703-5
Online ISBN: 978-1-84882-704-2
eBook Packages: MedicineMedicine (R0)